allos therapeutics - 500 Beiträge pro Seite

[mcrotznase]

Reger austausch im yahoo/us board über allos (alth)

Afterhours STRONG $3.42 / $10 soon
by: biotechvestor 01/26/04 08:37 pm
Msg: 6582 of 6594

FDA approval and this stock will fly to double digits. You guys think this company wasted 10 yrs and hundreds of millions if FDA wouldn`t approve? ALTH has a sharp management that knows FDA will approve. Fast track status was issued by FDA because they know this company has the only drug that`s RSR13 (efaproxiral) as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer. God Bless All

Dieses RSR13 ist gerade zur Zulassung
(so um den 04.Februar 04) . Soll ein super Medikament sein.

weiss jemand mehr darüber

[jobsti]

Hey,

habe ein bischen was über Firma und RSR13 rausgefunden:

Die Firma hat sich trotz der momentan vorherrschenden Börsenbaisse im letzten halben Jahr äusserst erfreulich entwickelt. Allos entwickelt einen niedrig molekularen Wirkstoff „RSR13“ zur Erhöhung der Sauerstoffabgabe der roten Blutkörperchen an das Gewebe. Dadurch kann der Verlauf einiger Krankheiten, bei welchen der Sauerstoffmangel entscheidend ist, positiv beeinflusst werden. Ausserdem erhöht dieses Präparat die Strahlenempfindlichkeit bösartiger Tumore und kann so eine Strahlentherapie unterstützen. Diese Substanz ist zur dritten klinischen Phase beantragt worden. Infolge der geringen Produktediversifikation handelt es sich bei Allos um eine Beteiligung mit einem relativ hohen Risiko.

Quelle:www.innomedica.ch/media/Halbjahresbericht_IMH_2002.pdf

Hoffe es hilft

[mcrotznase]

vielen dank für die schnelle aufklärung.

dem risiko bin ich mir bewusst aber ich habe eigentlich nur positive erfahrungen mit diesen "nieschenwerten" gemacht.

[bioperformer]

@ mcrotznase

Zu deiner Anfrage bezüglich ALTH und RSR13 haben die bisherigen Resonanzen sachlich eigentlich schon den Nagel auf den Kopf getroffen.
Ergänzend sei noch hinzugefügt, daß man sich bei ALTH seiner Sache - und somit der zu erwartenden Zulassung - ziemlich sicher zu sein scheint, da bereits im Herbst letzten Jahres Personal für damit verbundene Tätigkeitsfelder via Tagesboulevardpresse gesucht wurde.

Ist zwar alles kein Garant für eine endgültige Zulassung, das Chance/Risikoverhältnis ist meines Erachtens nach aber eher zugunsten der Chancen gewichtet.

Zusammengefasst: bei Ablehnung durch FDA trifft es das Unternehmen sicher äußerst heftig, bei Zulassung sind deutliche Ausschläge auf dem Kursbarometer zu erwarten. Wie hoch diese genauer ausfallen könnten, vermag wahrscheinlich aktuell niemand seriös nennen zu können.


Gruß vom Bio

[mcrotznase]

Schritt für Schritt zu neuen Ufern und neuen höheren
Aktienkursen (kleine Rückschläge einkalkuliert)!

Allos Therapeutics Initiates Phase I Study of RSR13 in Locally Advanced Non-Small Cell Lung Cancer
Wednesday January 28, 12:02 pm ET


WESTMINSTER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH - News) today announced the initiation of a Phase I clinical trial of RSR13 (efaproxiral) and supplemental oxygen with concurrent chemoradiation therapy in patients with locally advanced, unresectable (Stage IIIA/Stage IIIB) non-small cell lung cancer (NSCLC). The study will enroll up to 22 patients in three cohorts to test the safety and tolerability of escalating doses of RSR13 as an adjunct to thoracic radiation therapy.
ADVERTISEMENT


This clinical trial is an open-label, multi-center study of RSR13 administered to patients receiving a course of paclitaxel and carboplatin and concurrent thoracic radiation therapy. RSR13 plus supplemental oxygen will be administered prior to each fraction of thoracic radiation therapy.

"Concurrent chemoradiotherapy is considered the standard of care for patients with locally advanced non-small cell lung cancer in the United States," explained Pablo J. Cagnoni, M.D., Vice President, Clinical Development at Allos Therapeutics, Inc. "This will be the first time we examine RSR13 with concurrent chemoradiotherapy in patients with non-small cell lung cancer, and we are excited to evaluate the potential of RSR13 in this regimen."

In a previous Phase 2 trial, RSR13 showed a survival benefit compared with historical controls in patients with NSCLC when given with sequential chemoradiotherapy. The updated results, most recently presented at the European Society for Therapeutics Radiology and Oncology (ESTRO) in September of 2002, showed a median survival of 20.6 months, 1-year survival rate of 67 percent and a 2-year survival rate of 37 percent. The new Phase I trial will evaluate RSR13 given concurrently with chemoradiotherapy.

About Non-Small Cell Lung Cancer

Lung cancer is the most common cause of cancer death in the United States. According to the American Cancer Society, an estimated 171,900 new cases of lung cancer will be diagnosed this year, which account for about 14 percent of all cancer diagnoses. Non-small cell lung cancer is the most common type of lung cancer, accounting for almost 80 percent of lung cancer cases. More people die of lung cancer than of breast, prostate and colorectal cancers combined.

About RSR13

RSR13 is the first of a new class of pharmaceutical agents being developed as a radiation sensitizer to be used as an adjunct to radiation therapy. A synthetic small molecule, RSR13 decreases the hemoglobin-oxygen binding affinity, which facilitates the release of oxygen from hemoglobin. The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy in the treatment of cancer. By increasing the oxygenation of tumor tissues at the time of treatment, RSR13 has the potential to sensitize hypoxic (oxygen deprived) tissues and enhance the efficacy of standard radiation therapy. Allos has submitted a New Drug Application to the FDA for approval to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company`s lead clinical candidate, RSR13, is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin`s lymphoma. For more information, please visit the company`s web site at: www.allos.com.

This announcement contains forward-looking statements that involve risks and uncertainties. Future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the company`s ability to adequately demonstrate the safety and efficacy of RSR13 for use as a radiation sensitizer in the treatment of non-small cell lung cancer and any other type of cancer, and its ability to obtain regulatory approval for RSR13, as well as other risks and uncertainties detailed from time to time in the company`s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2002. All forward-looking statements are based on information currently available to the company on the date hereof, and the company assumes no responsibility to update such statements.

[mcrotznase]

Wieder mal was Neues! Langsam wird es unheimlich.

Sind ja ganz schön am rühren mit ihrem RSR 13 !?


Reuters
Allos cancer treatment to get quick review
Tuesday February 3, 6:25 am ET


NEW YORK, Feb 3 (Reuters) - Allos Therapeutics Inc. (NasdaqNM:ALTH - News) said on Tuesday the U.S. Food and Drug Administration (News - Websites) would accelerate its review of the company`s experimental treatment for brain cancer that has spread from breast cancer.
The treatment, called RSR13, is designed to be used along with brain radiation therapy for the treatment of brain metastases in patients with breast cancer.

Allos has already submitted its application to the FDA. The agency will decide by June whether to permit Allos to market the treatment.

[mcrotznase]

Jetzt sollte Bewegung reinkommen!!

Dow Jones Business News
Allos Therapeutics Says FDA Accepts Cancer Drug NDA
Tuesday February 3, 7:38 am ET


WESTMINSTER, Colo. (Dow Jones)--Allos Therapeutics Inc. (NasdaqNM:ALTH - News) said Tuesday that the Food and Drug Administration (News - Websites) has accepted for review its new drug application for RSR13, a cancer treatment.
In a press release, the Westminster, Colo., drug developer said the FDA has designated RSR13 for priority review, meaning it will take action by June 2004.

The company is seeking approval to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer. The filing was based on a 538-patient Phase 3 study.

Company Web site: http://www.allos.com

-Chad Bray; Dow Jones Newswires; 201-938-5400

[mcrotznase]

nur mal so!
Allos Therapeutics Inc. (NasdaqNM:ALTH - News) jumped before the open, after the company said regulators would accelerate a review of its experimental treatment for brain cancer that has spread from breast cancer.

Allos shares rose more than 17 percent to $4.12 on Instinet, up from their Nasdaq close of $3.51.

Allos said it has already submitted its application to the U.S. Food and Drug Administration (News - Websites) , which will decide by June whether to permit Allos to market the treatment

[mcrotznase]

Morgen Zahlen und dann die Zulassung !?
Gestern 8% rauf. Was kann man da erwarten. Sollen ja nicht viel Aktien in Umlauf sein.

[mcrotznase]

vorbörslich 2 % sieht ja schon wieder gut aus

[mcrotznase]

ohne kommentar !!

Allos Therapeutics ALTH CE Unterberg Towbin from LT Mkt Perforn
to LT Buy History